Natera was proud to deliver a clinically focused seminar at the recent Maternity Midwifery and Baby London 2017 conference.
The event was attended by hundreds of midwives and allied health professionals, all of whom were engaged with learning more about the problems that 22q microdeletion can pose to mothers and children.
There was an excellent turnout for the session on Prenatal 22q11 screening for 22q11.2 microdeletion. The session covered what a microdeletion is, and how prenatal detection of 22q11.2 can have an impact on management in pregnancy, at delivery, in the neonatal period and beyond.
Ethical issues and professional society guidelines relating to prenatal screening were also discussed. The session aimed to generate discussion about prenatal screening for 22q11.2 and to raise awareness of this important condition. The MMB conference offered an excellent forum in which to accomplish these aims.
Panorama is now available in the United Kingdom in partnership with NewGene Ltd, an ISO:15189 accredited laboratory company. NewGene provides a range of genetic analysis and diagnostic services to the NHS, commercial R&D partners, and healthcare providers across Europe.